Fred Aslan, Artiva Biotherapeutics CEO

Arti­va boasts ear­ly NK cell ther­a­py re­sults, giv­ing life­line to part­ner Af­fimed

Arti­va Bio­ther­a­peu­tics re­port­ed ear­ly da­ta on its off-the-shelf NK cell ther­a­py in com­bi­na­tion with rit­ux­imab, sug­gest­ing the com­bo could shrink tu­mors in non-Hodgkin lym­phoma pa­tients who have al­ready tried many oth­er can­cer ther­a­pies.

Four of six pa­tients who re­ceived the com­bo ther­a­py of AB-101 and rit­ux­imab saw their tu­mors shrink, and three of those six saw signs of can­cer go away com­plete­ly, ac­cord­ing to an AS­CO ab­stract re­leased Thurs­day evening. Three of the pa­tients who re­spond­ed to treat­ment have had on­go­ing re­spons­es of five, sev­en and nine months.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters